73 results on '"Abraham, Ivo"'
Search Results
2. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma
3. The economic burden of Ebola virus disease: a review and recommendations for analysis
4. What to expect in 2024: important health economics and outcomes research (HEOR) trends
5. What to Expect in 2024: Important Health Economics and Outcomes Research (HEOR) Trends
6. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries
7. Preparing for the third decade of biosimilars
8. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region
9. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey
10. Journal of Medical Economics in review: high impact articles from 2022
11. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: Simulation study
12. The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer
13. The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention
14. Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment
15. Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning
16. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?
17. Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence
18. Journal of Medical Economics in review: the best of 2021
19. Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities
20. Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL
21. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy
22. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries
23. Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma
24. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis
25. Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients
26. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data
27. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer
28. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment
29. ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis
30. Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients
31. Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
32. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv
33. The six Delta platform for outcome-based contracting for pharmaceuticals
34. Pricing methods in outcome-based contracting: δ6: adherence-based pricing
35. Pricing methods in outcome-based contracting: δ3: reference-based pricing
36. Pricing methods in outcome-based contracting: δ4: safety-based pricing
37. Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing
38. Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing
39. Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)
40. Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing
41. Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
42. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim
43. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1
44. Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis
45. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance
46. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma
47. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018
48. Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study
49. Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure
50. Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.